• HALO: AJOVY may give your patients more migraine-free days vs placebo.¹

  Select the data:

  Chronic migraine

  Episodic migraine

• HALO: AJOVY may help patients reduce migraine by 50% or more.¹

  Select the data:

  Chronic migraine

  Episodic migraine

• FOCUS: AJOVY was studied in patients with an inadequate response to 2 or more classes of prior preventive treatments.²

  Results from the phase 3b FOCUS study

HALO: With AJOVY, patients experienced significantly more migraine-free days vs placebo¹

In chronic migraine, a reduction in monthly headache days of at least moderate severity was demonstrated during the 12-week period (primary endpoint), with results seen as early as week 1^1,2

Chronic Migraine

REDUCTION IN MONTHLY HEADACHE DAYS OF AT LEAST MODERATE SEVERITY (PRIMARY ENDPOINT)^1,2

Patients with a mean baseline of 12.8 headache days of at least moderate severity per month experienced¹:

4.6 fewer headache days per month, on average, with monthly dosing (vs 2.5 days with placebo)¹*

Patients with a mean baseline of 13.2 headache days of at least moderate severity per month experienced¹:

4.3 fewer headache days per month, on average, with quarterly dosing (vs 2.5 days with placebo)¹*

 *P<0.001.¹

In episodic migraine, a reduction in monthly migraine days was demonstrated during the 12-week period (primary endpoint), with results seen as early as week 1^1,2

Episodic Migraine

REDUCTION IN MONTHLY MIGRAINE DAYS (PRIMARY ENDPOINT)^1,2

Patients with a mean baseline of 8.9 migraine days per month experienced¹:

3.7 fewer migraine days per month, on average, with monthly dosing (vs 2.2 days with placebo)^1†

Patients with a mean baseline of 9.2 migraine days per month experienced¹:

3.4 fewer migraine days per month, on average, with quarterly dosing (vs 2.2 days with placebo)^1†

 ^†P<0.001.¹

Patients with chronic and episodic migraine receiving AJOVY had a significant reduction in the use of acute medication vs placebo (secondary endpoint)^1,2‡

 

^‡ Reduction of acute medication use (secondary endpoint): Patients in the chronic migraine trial with a mean baseline of 13.1 days for both monthly and quarterly dosing and 13.0 days for placebo saw a mean reduction of: 4.2 days for monthly dosing, 3.7 days for quarterly dosing vs 1.9 days with placebo, P<0.001. Patients in the episodic migraine trial with a mean baseline of 7.7 days for monthly dosing, 7.8 days for quarterly dosing, and 7.7 days for placebo saw a mean reduction of: 3.0 days for monthly dosing, 2.9 days for quarterly dosing vs 1.6 days with placebo, P<0.001.^1,2

SEE HALO STUDY DESIGNS

HALO: AJOVY reduced migraine days by 50% or more¹

Chronic Migraine

PATIENTS ACHIEVING AT LEAST A 50% REDUCTION IN MONTHLY AVERAGE HEADACHE DAYS OF AT LEAST MODERATE SEVERITY (SECONDARY ENDPOINT)¹

37.6% of patients with chronic migraine achieved at least a 50% reduction in monthly average headache days with quarterly dosing vs 18.1% for placebo¹*

^‡P<0.001.¹

1 in 5 patients with chronic migraine experienced a 75% reduction in monthly average headache days vs 1 in 10 with placebo (post hoc analysis)^2†

Episodic Migraine

PATIENTS ACHIEVING AT LEAST A 50% REDUCTION IN MONTHLY AVERAGE MIGRAINE DAYS (SECONDARY ENDPOINT)¹

44.4% of patients with episodic migraine achieved at least a 50% reduction in monthly average migraine days with quarterly dosing vs 27.9% for placebo^1‡

^‡P<0.001.¹

1 in 4 patients with episodic migraine experienced a 75% reduction in monthly average migraine days vs ~1 in 7 with placebo (post hoc analysis)^2†

 

^†For all post hoc analyses, no determination of statistical significance can be made and no conclusions should be drawn.

SEE HALO STUDY DESIGNS

FOCUS
was the largest study of its kind (N=838) in patients with inadequate response to 2 or more classes of prior preventive treatments³

Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study, evaluating efficacy and safety of quarterly and monthly treatment with AJOVY, compared to placebo in patients with chronic or episodic migraine who had experienced inadequate response* to 2 to 4 classes of prior preventive treatments

^*Inadequate response to a prior medication was defined as: (1) no clinically meaningful improvement after at least 3 months (2) patient could not tolerate the drug (3) drug was contraindicated for patient or (4) drug was not suitable for the patient.³

FOCUS: Significant reduction in average monthly migraine days compared to placebo after inadequate response to 2 or more classes of preventive treatments (primary endpoint)³

Change from baseline in average monthly mIgraine days during the focus phase 3b study³

Improvements were seen as early as week 1 and were sustained throughout the 3-month treatment period (exploratory endpoint)^2†

FOCUS: Patients who achieved ≥50% reduction in monthly average migraine days³

Percentage of patients achieving ≥50% reduction in average monthly migraine days vs placebo during the 12-week study period (secondary endpoint)³

34% of patients achieved a ≥50% reduction of average monthly migraine days with either quarterly or monthly dosing vs 9% for placebo (P<0.0001) (secondary endpoint)³

FOCUS: Results in patients with an inadequate response to anticonvulsants or neurotoxins (exploratory analysis)^†

• 3.8 mean reduction from baseline in monthly average migraine days for both quarterly and monthly arms vs 1.0 for placebo in patients with previous anticonvulsant use²
• 2.7 and 3.2 mean reduction from baseline in monthly average migraine days for quarterly and monthly arms, respectively, vs 0.2 for placebo in patients who previously used neurotoxins²

FOCUS: Patients experienced a significant reduction in the monthly average number of days using migraine-specific acute headache medication (secondary endpoint)²

• Mean reduction of 3.7 days for quarterly dosing and 3.9 days for monthly dosing of migraine-specific acute headache medication use vs 0.6 days with placebo²

^†For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.

Suggestions to explore next